Angelini Pharma to acquire Arvelle Therapeutics and with it cenobamate.

Angelini Pharma, an international pharmaceutical company which is a part of the private Italian Angelini Group – and Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, announced that they have concluded a definitive merger agreement under which Angelini Pharma will acquire Arvelle Therapeutics in an all cash transaction for a total aggregate valuation of up to $960 million. Following regulatory approval, $610 million will be paid. Subsequently, and subject to cenobamate reaching certain revenue targets, a further $350 million will be paid.